EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?

Koubaa Afifa, Sriha Belguith Asma, Harzallah Nabil, Bellaleh Ahlem, Sahtout Mounira, Younes Kawthar, Triki Sonia, Hellara Ilhem, Neffati Fadoua, Najjar Fadhel, Soltani Mohamed

International Journal of Chronic Diseases · 2016 · 2016 · 1-7

DOI: 10.1155/2016/2910627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Diseases, 2016. Verfasst von Koubaa Afifa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stah Jabeur Primary Health Center, Monastir Health Group, 5000 Monastir, Tunisia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity.

Methods

We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard.

Results

Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient ( p = 0.001 ). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men ( p = 0.008 ) and 0.80 when diabetes duration exceeds 5 years ( p = 0.001 ). The MA value at 100% Sp for MT was 35 mg/L.

Conclusion

The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks.

Autor:innen und Institutionen

  • Stah Jabeur Primary Health Center, Monastir Health Group, 5000 Monastir, Tunisia.
  • Department of Preventive Medicine and Epidemiology, Faculty of Medicine, Monastir, Tunisia.
  • Primary Health Center, Monastir Health Group, Monastir, Tunisia.
  • Department of Pathology, Monastir, Tunisia.
  • C2 Primary Health Center, Monastir Health Group, Monastir, Tunisia.
  • Biochemistry Laboratory, Faculty of Pharmacy, Monastir, Tunisia.

Zitieren

APA

Afifa, K., Belguith Asma, S., Nabil, H., Ahlem, B., Mounira, S., Kawthar, Y., Sonia, T., Ilhem, H., Fadoua, N., Fadhel, N., & Mohamed, S. (2016). Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?. International Journal of Chronic Diseases, 2016, 1-7. https://doi.org/10.1155/2016/2910627

Vancouver

Afifa K, Belguith Asma S, Nabil H, Ahlem B, Mounira S, Kawthar Y, et al. Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?. International Journal of Chronic Diseases. 2016;2016:1-7. doi:10.1155/2016/2910627

BibTeX
@article{Afifa2016,
  author = {Afifa, Koubaa and Belguith Asma, Sriha and Nabil, Harzallah and Ahlem, Bellaleh and Mounira, Sahtout and Kawthar, Younes and Sonia, Triki and Ilhem, Hellara and Fadoua, Neffati and Fadhel, Najjar and Mohamed, Soltani},
  title = {Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?},
  journal = {International Journal of Chronic Diseases},
  year = {2016},
  volume = {2016},
  pages = {1--7},
  doi = {10.1155/2016/2910627}
}
Kostenlos starten →